Daniel Gibbs had received only four monthly doses of Biogens experimental Alzheimers drug in a clinical trial in 2017 when he ended up in an intensive care unit.He had an excruciating headache, and his blood pressure was so high that doctors thought he might be having a stroke.

It turned out that the retired Portland, Ore., neurologist who had treated Alzheimers patients before he was diagnosed with the disease himself in 2015 was experiencing some of the worst reported side effects of the drug. Doctors prescribed medicines to lower his blood pressure, which reached 206/116, and later to reduce brain swelling. But for weeks afterward, he struggled to read, follow conversations, and do simple math. He recovered but never again took the Alzheimers drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

Continued here:
Retired neurologist with Alzheimer's knows firsthand the risks of Aduhelm - STAT - STAT